Suzuki, Tomotaka
Kusumoto, Shigeru
Yamashita, Taro
Masuda, Arisa
Kinoshita, Shiori
Yoshida, Takashi
Takami-Mori, Fumiko
Takino, Hisashi
Ito, Asahi
Ri, Masaki
Ishida, Takashi
Komatsu, Hirokazu
Ueda, Mitsuharu
Ando, Yukio
Inagaki, Hiroshi
Iida, Shinsuke
Funding for this research was provided by:
Amyloidosis Research Committee from the Ministry of Health, Labour, and Welfare, Japan
Article History
Received: 3 April 2015
Accepted: 5 November 2015
First Online: 10 November 2015
Compliance with ethical standards
:
: This study was supported in part by the Amyloidosis Research Committee from the Ministry of Health, Labour and Welfare, Japan.
: Shinsuke Iida has received research funding from Bristol-Myers Squibb Co., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Celgene K.K., Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., and honoraria from Celgene K.K., Janssen Pharmaceutical K.K. and Ono Pharmaceutical Co. Ltd.Takashi Ishida has received research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and Celgene K.K., and honoraria from Kyowa Hakko Kirin Co., Ltd.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of retrospective study, formal consent was not required.